Research Collaboration on Therapy for Bone Diseases

An agreement to have an evaluation of the therapeutic potential of its synthetic growth factors to treat diseases of bone and cartilage has been announced by Millenium Biologix, Inc. (MBI, Kingston, Canada). The evaluation will be conducted by P&G Pharmaceuticals (Cincinnati, OH, USA).

Millenium has developed synthetic BCSP (bone and cartilage stimulating peptides) growth factors to treat diseases of bone and cartilage. During Millenium's development work for orthopedic implant and ex vivo tissue engineering applications, the systemic drug potential of BCSP was studied. The encouraging results led to the current collaboration. Millenium has granted P&G an option for the compounds, and terms for a worldwide license to P&G have been outlined.

"This agreement will be very important in realizing the full potential of our novel synthetic peptides,” said Sydney Pugh, president and CEO of Millenium. "We are also excited that this agreement may not only lead to development of beneficial new drugs; it opens up the possibility to further tap the significant opportunities that we believe lie at the interface between the pharmaceutical and biomedical device sectors.”





Related Links:
Millenium Biologix
P&G Pharma